ResApp Health Limited is an Australian smartphone app developed to detect respiratory illness and get better results than experienced doctors. According to their website, ResApp is developing digital healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease. Some of these diseases include pneumonia, asthma and bronchitis.
The app uses the sounds of one’s cough or breathing to diagnose the problem. Doctors currently rely on hearing certain sounds through a stethoscope. ResApp’s algorithms were more than 89% accurate when used to differentiate between patients with lower respiratory tract disease and patients with upper respiratory tract infections.
Their shares were up 2.6% to $0.26 in early trade. Dr Tony Keating, CEO of ResApp said, “We are pleased to again report high levels of accuracy on a dataset that is more than 50% larger than the previously used dataset. These updated results reaffirms the algorithm’s clinical accuracy right before we enter pivotal studies needed for our upcoming premarket submission to the US Food and Drug Administration.”